|
JP6093712B2
(ja)
|
2010-12-22 |
2017-03-08 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン２のスーパーアゴニストおよびアンタゴニスト
|
|
JP6463672B2
(ja)
*
|
2012-05-25 |
2019-02-06 |
セレクティスＣｅｌｌｅｃｔｉｓ |
Ｔｃｒアルファ欠損ｔ細胞を増殖させるためのプレｔアルファまたはその機能性変種の使用
|
|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
PT3300745T
(pt)
|
2013-02-15 |
2019-11-27 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
|
US9944690B2
(en)
|
2013-03-14 |
2018-04-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
ES2910004T3
(es)
*
|
2013-07-29 |
2022-05-11 |
2Seventy Bio Inc |
Proteínas de señalización de múltiples partes y sus usos
|
|
CA2925421C
(en)
|
2013-09-24 |
2023-08-29 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
|
PT3083689T
(pt)
|
2013-12-17 |
2020-08-27 |
Genentech Inc |
Anticorpos anti-cd3 e métodos de utilização
|
|
EP4420663A3
(en)
*
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP3094354B1
(en)
*
|
2014-01-14 |
2018-10-17 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
|
CA2937750A1
(en)
|
2014-02-14 |
2015-08-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
|
EP3811970A1
(en)
*
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
PL3888674T3
(pl)
|
2014-04-07 |
2024-09-23 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
|
EP3134514B1
(en)
|
2014-04-23 |
2019-09-18 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
JP2017518053A
(ja)
*
|
2014-06-06 |
2017-07-06 |
メモリアル スローン−ケタリング キャンサー センター |
メソセリン標的化キメラ抗原受容体およびその使用
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
KR102818922B1
(ko)
*
|
2014-08-28 |
2025-06-11 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
AU2015310897B2
(en)
|
2014-09-04 |
2020-03-19 |
Cellectis |
Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
BR112017005390A2
(pt)
*
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
|
|
EP3201322A4
(en)
*
|
2014-10-03 |
2018-05-30 |
Yale University |
Innate immune system modification for anticancer therapy
|
|
RU2017115808A
(ru)
*
|
2014-10-07 |
2018-11-13 |
Селлектис |
Способ модуляции активности car-индуцированных иммунных клеток
|
|
IL279420B2
(en)
|
2014-10-08 |
2024-09-01 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
BR112017011771A2
(pt)
*
|
2014-12-02 |
2018-07-10 |
Prospect Chartercare Rwmc Llc |
métodos e composições para o tratamento de câncer
|
|
WO2016090329A2
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
|
CA2969864A1
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
WO2016100241A2
(en)
*
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled activation or elimination of therapeutic cells
|
|
DK3240805T3
(da)
|
2014-12-15 |
2025-02-10 |
Univ California |
Bispecifik or-gate kimærisk antigenreceptor, som reagerer på cd19 og cd20
|
|
WO2016098078A2
(en)
*
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
JP6718450B2
(ja)
*
|
2014-12-19 |
2020-07-08 |
イーティーエッチ チューリッヒ |
キメラ抗原受容体及びその使用方法
|
|
MX387665B
(es)
|
2014-12-24 |
2025-03-18 |
Aadigen Llc |
Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
|
|
RU2021118125A
(ru)
|
2014-12-29 |
2022-04-06 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
GB201503133D0
(en)
|
2015-02-24 |
2015-04-08 |
Ucl Business Plc And Syncona Partners Llp |
Chimeric protein
|
|
CN114230670B
(zh)
|
2015-02-27 |
2025-06-03 |
美商生物细胞基因治疗有限公司 |
靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法
|
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
|
GB201504840D0
(en)
*
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
JP6890546B2
(ja)
*
|
2015-04-02 |
2021-06-18 |
メモリアル スローン ケタリング キャンサー センター |
Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法
|
|
HRP20220893T1
(hr)
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
EP3283113A4
(en)
*
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP3447075B1
(en)
|
2015-05-15 |
2023-08-09 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
IL255697B2
(en)
|
2015-05-18 |
2023-11-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR programming using fusion proteins
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
JP6961497B2
(ja)
*
|
2015-06-25 |
2021-11-05 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CA2992551A1
(en)
*
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
CN108026534B
(zh)
|
2015-08-05 |
2021-08-31 |
赛莱博迈德公司 |
嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
|
|
CN108350062B
(zh)
|
2015-08-06 |
2022-10-14 |
达纳-法伯癌症研究所股份有限公司 |
靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
|
|
EP3331913A1
(en)
*
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3341410B1
(en)
|
2015-08-24 |
2021-06-02 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
SG10201913915WA
(en)
|
2015-09-01 |
2020-03-30 |
Univ California |
Modular polypeptide libraries and methods of making and using same
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
KR20180053744A
(ko)
|
2015-09-23 |
2018-05-23 |
사이토이뮨 테라퓨틱스 엘엘씨 |
면역 요법을 위한 flt3 유도된 car 세포
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
WO2017087723A1
(en)
*
|
2015-11-19 |
2017-05-26 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
JP7621053B2
(ja)
*
|
2015-11-23 |
2025-01-29 |
トラスティーズ オブ ボストン ユニバーシティ |
キメラ抗原受容体に関する方法および組成物
|
|
AU2016369519B2
(en)
|
2015-12-16 |
2023-04-20 |
Seattle Project Corp. |
Neoantigen identification, manufacture, and use
|
|
EP3184548A1
(en)
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
|
US20190269727A1
(en)
|
2015-12-28 |
2019-09-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3399991A4
(en)
*
|
2016-01-08 |
2019-08-07 |
The Regents of The University of California |
REQUIRES ACTIVE HETERODIMER POLYPEPTIDES AND METHOD FOR USE THEREOF
|
|
MY196175A
(en)
|
2016-01-11 |
2023-03-20 |
Univ Leland Stanford Junior |
Chimeric Proteins And Methods Of Regulating Gene Expression
|
|
AU2017207281B2
(en)
|
2016-01-11 |
2022-03-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of immunotherapy
|
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
|
GB201602571D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
GB201602563D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
US10871490B2
(en)
|
2016-02-29 |
2020-12-22 |
Multenyi Biotec, gmbH |
Assay for detection of chimeric antigen receptor T cells
|
|
CN109715207B
(zh)
*
|
2016-03-29 |
2023-03-31 |
南加利福尼亚大学 |
靶向癌症的嵌合抗原受体
|
|
US11768203B2
(en)
|
2016-03-31 |
2023-09-26 |
University Of Southern California |
Highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
CU20180121A7
(es)
|
2016-04-01 |
2019-05-03 |
Kite Pharma Inc |
Receptores de antígenos quiméricos y células t
|
|
UA128781C2
(uk)
|
2016-04-01 |
2024-10-23 |
Кайт Фарма, Інк. |
Т-клітина, спосіб її отримання та застосування
|
|
IL296966A
(en)
|
2016-04-01 |
2022-12-01 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
|
KR102522622B1
(ko)
|
2016-04-01 |
2023-04-18 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
AU2017250769B2
(en)
|
2016-04-15 |
2022-07-14 |
Memorial Sloan Kettering Cancer Center |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
|
WO2017197234A1
(en)
|
2016-05-13 |
2017-11-16 |
Bioatla, Llc |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
|
CN109715668A
(zh)
|
2016-08-02 |
2019-05-03 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重编程的组合物和方法
|
|
EP3344263A4
(en)
|
2016-08-04 |
2020-07-01 |
Memorial Sloan-Kettering Cancer Center |
CANCER ANTIGEN TARGETS AND USES THEREOF
|
|
WO2018045034A1
(en)
|
2016-08-30 |
2018-03-08 |
Promab Biotechnologies, Inc. |
Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN107793483B
(zh)
*
|
2016-09-06 |
2019-08-23 |
伍志强 |
嵌合抗原受体及其基因和重组表达载体、carmsln-nkt细胞及其制备方法和应用
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US10683355B2
(en)
|
2016-09-16 |
2020-06-16 |
Kissei Pharmaceutical Co., Ltd. |
Genetically-modified cells and method for producing same
|
|
EP3523326B1
(en)
*
|
2016-10-04 |
2020-06-03 |
Precision Biosciences, Inc. |
Co-stimulatory domains for use in genetically-modified cells
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
CA3041284A1
(en)
*
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
|
JP7206214B2
(ja)
*
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
EP3568406A4
(en)
*
|
2017-01-10 |
2020-10-21 |
The General Hospital Corporation |
T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
|
|
CN107573419A
(zh)
*
|
2017-01-24 |
2018-01-12 |
深圳市体内生物医药科技有限公司 |
一种增强t细胞抗肿瘤活性的核酸分子
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
AU2018219289A1
(en)
|
2017-02-08 |
2019-09-05 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
CA3055202A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
|
US20180280437A1
(en)
|
2017-03-13 |
2018-10-04 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
CN117384929A
(zh)
|
2017-03-27 |
2024-01-12 |
新加坡国立大学 |
一种编码由细胞表达的嵌合受体的多核苷酸
|
|
RU2019128544A
(ru)
|
2017-03-27 |
2021-04-28 |
Нэшнл Юниверсити Оф Сингапур |
Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
|
|
JOP20180027A1
(ar)
|
2017-03-28 |
2019-01-30 |
Cell Design Labs Inc |
بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
|
|
CN110582280B
(zh)
*
|
2017-03-31 |
2024-03-19 |
小利兰·斯坦福大学托管委员会 |
通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
KR20240059648A
(ko)
|
2017-04-19 |
2024-05-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
조작된 항원 수용체를 발현하는 면역 세포
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
AU2018265242B2
(en)
*
|
2017-05-12 |
2024-01-18 |
Cellectis |
Protease based switch chimeric antigen receptors for safer cell immunotherapy
|
|
EP3634989A1
(en)
*
|
2017-05-15 |
2020-04-15 |
Autolus Limited |
A cell comprising a chimeric antigen receptor (car)
|
|
CN107141356B
(zh)
*
|
2017-06-07 |
2020-03-13 |
胜武（北京）生物科技有限公司 |
一种光诱导二聚体型嵌合抗原受体
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
|
JP7433051B2
(ja)
|
2017-06-19 |
2024-02-19 |
メディシナ セラピューティクス インコーポレイテッド |
Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
|
|
CA3070578A1
(en)
|
2017-06-21 |
2018-12-27 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
CN107446937B
(zh)
*
|
2017-09-05 |
2020-12-25 |
深圳华云生物技术有限公司 |
嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
|
|
CN111315769A
(zh)
*
|
2017-09-06 |
2020-06-19 |
加州理工学院 |
信号传导和抗原呈递双功能受体(sabr)
|
|
CN109504697A
(zh)
*
|
2017-09-15 |
2019-03-22 |
上海恒润达生生物科技有限公司 |
一种靶向人源化mesothelin的嵌合抗原受体的方法和用途
|
|
AU2018335266A1
(en)
*
|
2017-09-22 |
2020-02-06 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chimeric antigen receptors with enhanced NFκB signaling
|
|
CN109553686A
(zh)
*
|
2017-09-26 |
2019-04-02 |
南京安吉生物科技有限公司 |
一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
|
|
GB201715918D0
(en)
*
|
2017-09-29 |
2017-11-15 |
Tc Biopharm Ltd |
Modified CAR-T
|
|
WO2019067677A1
(en)
|
2017-09-29 |
2019-04-04 |
Cell Design Labs, Inc. |
METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
|
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
PROCEDURES AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANT GENE SIGNATURE IN CANCER
|
|
CA3078744A1
(en)
|
2017-10-10 |
2019-04-18 |
Gritstone Oncology, Inc. |
Neoantigen identification using hotspots
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
SG11202003177RA
(en)
|
2017-10-25 |
2020-05-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
AU2018373154B2
(en)
|
2017-11-22 |
2025-08-07 |
Seattle Project Corp. |
Reducing junction epitope presentation for neoantigens
|
|
EP3723787A4
(en)
*
|
2017-12-14 |
2021-09-01 |
Bluebird Bio, Inc. |
DARIC INTERLEUKIN RECEPTORS
|
|
US12187776B2
(en)
|
2017-12-14 |
2025-01-07 |
Celyad S.A. |
Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
|
|
EP3502130A1
(en)
|
2017-12-20 |
2019-06-26 |
St. Anna Kinderkrebsforschung |
Ligand regulated protein-protein interaction system
|
|
KR20250128387A
(ko)
|
2017-12-20 |
2025-08-27 |
세인트 안나 킨더크렙스포르슝 |
리간드 조절 단백질-단백질 상호작용 시스템
|
|
US20190194617A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
|
BR112020011017A2
(pt)
|
2017-12-22 |
2020-11-17 |
Fate Therapeutics, Inc. |
células efetoras imunes intensificadas e uso das mesmas
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
WO2019134950A1
(en)
|
2018-01-04 |
2019-07-11 |
Miltenyi Biotec Gmbh |
Chimeric antigen receptor specific for bdca2 antigen
|
|
CN112055595B
(zh)
|
2018-01-22 |
2024-12-17 |
恩多塞特公司 |
Car t细胞的使用方法
|
|
CN108017717B
(zh)
*
|
2018-01-24 |
2019-08-16 |
首都医科大学宣武医院 |
一种用于体外高效定向扩增的嵌合抗原受体及其应用
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
US20210023170A1
(en)
*
|
2018-02-12 |
2021-01-28 |
University Of Florida Research Foundation, Incorporated |
Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
|
|
KR102618231B1
(ko)
|
2018-02-16 |
2023-12-28 |
카이트 파마 인코포레이티드 |
변형된 만능성 줄기 세포, 및 제조 및 사용 방법
|
|
CN111918661A
(zh)
|
2018-02-21 |
2020-11-10 |
得克萨斯大学体系董事会 |
用于活化和扩增自然杀伤细胞的方法及其用途
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
AU2019227813B2
(en)
|
2018-02-27 |
2024-06-27 |
Seattle Project Corp. |
Neoantigen identification with pan-allele models
|
|
EP4495246A3
(en)
|
2018-03-01 |
2025-03-26 |
University of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
WO2019166453A1
(en)
*
|
2018-03-01 |
2019-09-06 |
F. Hoffmann-La Roche Ag |
Specificity assay for novel target antigen binding moieties
|
|
CN112004829A
(zh)
*
|
2018-03-12 |
2020-11-27 |
南克维斯特公司 |
Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
|
|
WO2019175209A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Medigene Immunotherapies Gmbh |
Inducible t cell receptors and uses thereof
|
|
EP3775228A4
(en)
|
2018-03-29 |
2022-02-23 |
Fate Therapeutics, Inc. |
ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
US20210023136A1
(en)
*
|
2018-04-06 |
2021-01-28 |
The Regents Of The University Of California |
Trans-antigen targeting in heterogeneous cancers and methods of use thereof
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
WO2019195586A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
WO2019200007A1
(en)
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
|
CN108410908B
(zh)
*
|
2018-04-12 |
2021-08-03 |
吉林大学 |
一种利用植物激素ga及小分子物质pac调节细胞通路的方法
|
|
EP3774866A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Ludwig Institute for Cancer Research Ltd |
Heterodimeric inactivatable chimeric antigen receptors
|
|
KR102251028B1
(ko)
|
2018-04-18 |
2021-05-12 |
앱클론(주) |
스위치 분자 및 스위처블 키메라 항원 수용체
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
CN112041436A
(zh)
|
2018-04-27 |
2020-12-04 |
西雅图儿童医院（Dba西雅图儿童研究所） |
雷帕霉素抗性细胞
|
|
CN108715616A
(zh)
*
|
2018-04-27 |
2018-10-30 |
上海恒润达生生物科技有限公司 |
靶向人源化间皮素的嵌合抗原受体方法和用途
|
|
US12473342B2
(en)
|
2018-04-27 |
2025-11-18 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
IL321548A
(en)
*
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
EP3802579A1
(en)
|
2018-06-01 |
2021-04-14 |
The Board of Trustees of the Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
CN110577604A
(zh)
*
|
2018-06-07 |
2019-12-17 |
亘喜生物科技（上海）有限公司 |
携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
EP3810645A1
(en)
|
2018-06-22 |
2021-04-28 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
CN110669138A
(zh)
*
|
2018-07-02 |
2020-01-10 |
中国药科大学 |
一种双嵌合抗原受体、t细胞及其构建方法与应用
|
|
EP3821012A4
(en)
|
2018-07-13 |
2022-04-20 |
The Regents of The University of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
|
EP3823993A1
(en)
|
2018-07-18 |
2021-05-26 |
Amgen Inc. |
Chimeric receptors to steap1 and methods of use thereof
|
|
IL280659B2
(en)
|
2018-08-09 |
2024-11-01 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
CN113166736A
(zh)
|
2018-08-13 |
2021-07-23 |
奥尔胡斯大学 |
具有改变的激动剂特异性和亲和性的基因改变的LysM受体
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
EP3844267B1
(en)
|
2018-08-31 |
2025-06-25 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020050993A2
(en)
*
|
2018-09-07 |
2020-03-12 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020070289A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
CN113164576A
(zh)
*
|
2018-10-05 |
2021-07-23 |
圣安娜儿童癌症研究中心 |
嵌合抗原受体(car)组
|
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816839D0
(en)
*
|
2018-10-16 |
2018-11-28 |
Glaxosmithkline Ip Dev Ltd |
Novel control switch
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
CA3121128A1
(en)
|
2018-12-02 |
2020-06-11 |
Fate Therapeutics, Inc. |
Immunotherapies using enhanced ipsc derived effector cells
|
|
CN113260633A
(zh)
|
2018-12-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
用于癌症免疫疗法的诊断方法和组合物
|
|
WO2020118305A1
(en)
*
|
2018-12-07 |
2020-06-11 |
The Trustees Of Columbia University In The City Of New York |
Muc4 car-t cells for treating cancer
|
|
MX2021006968A
(es)
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020141106A1
(en)
|
2019-01-03 |
2020-07-09 |
Kemijski Institut |
Engineered externally regulated artificial transcription regulatory system based on engineered nfat
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US20220133791A1
(en)
|
2019-01-23 |
2022-05-05 |
Miltenyi Biotec B.V. & Co. KG |
A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
AU2020231308B2
(en)
|
2019-03-01 |
2025-11-27 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
|
EP3773918A4
(en)
*
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US20220193137A1
(en)
|
2019-04-04 |
2022-06-23 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
AU2020259449A1
(en)
|
2019-04-17 |
2021-12-09 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of molecules
|
|
BR112021021178A2
(pt)
|
2019-04-26 |
2022-03-15 |
Allogene Therapeutics Inc |
Receptores de antígeno quimérico resistentes ao rituximabe e usos destes
|
|
AU2020261411B2
(en)
|
2019-04-26 |
2025-10-02 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car T cells
|
|
US20220184131A1
(en)
|
2019-05-01 |
2022-06-16 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
AU2020267349A1
(en)
|
2019-05-04 |
2021-11-11 |
Inhibrx Biosciences, Inc. |
CLEC12a-binding polypeptides and uses thereof
|
|
US11840575B2
(en)
*
|
2019-05-07 |
2023-12-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cells targeting BCMA and their uses thereof
|
|
WO2020224605A1
(zh)
*
|
2019-05-07 |
2020-11-12 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
EP3966249A4
(en)
|
2019-05-08 |
2023-05-10 |
2seventy bio, Inc. |
Cll-1 targeted immunotherapies
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
JP7606472B2
(ja)
|
2019-05-28 |
2024-12-25 |
ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー |
遺伝子改変ｔ細胞の生成方法
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
CN114391021A
(zh)
|
2019-06-21 |
2022-04-22 |
凯德药业股份有限公司 |
TGF-β受体和使用方法
|
|
EP4004030A1
(en)
*
|
2019-07-24 |
2022-06-01 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptor t cells and uses thereof
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021047804A1
(en)
|
2019-09-11 |
2021-03-18 |
Miltenyi Biotec B.V. & Co. KG |
In vitro method for transduction of t cells in the presence of malignant cells
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
EP4041893A4
(en)
*
|
2019-10-08 |
2023-08-30 |
Provincial Health Services Authority |
CHEMERACY CYTOKINE RECEPTORS
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
EP4069728A4
(en)
*
|
2019-12-03 |
2023-12-27 |
University of Massachusetts |
COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY
|
|
CN113087805A
(zh)
*
|
2019-12-31 |
2021-07-09 |
华东师范大学 |
一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用
|
|
CN115279381A
(zh)
*
|
2020-01-13 |
2022-11-01 |
恩卡尔塔公司 |
Bcma定向性细胞免疫疗法组合物和方法
|
|
KR20220130158A
(ko)
|
2020-01-23 |
2022-09-26 |
더 칠드런스 메디칼 센터 코포레이션 |
인간 만능 줄기 세포로부터의 무-간질 t 세포 분화
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
WO2021156277A1
(en)
|
2020-02-04 |
2021-08-12 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
WO2021162521A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
(주)이뮤노텍바이오팜코리아 |
외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
US20230256017A1
(en)
|
2020-02-27 |
2023-08-17 |
Jennifer Brogdon |
Methods of making chimeric antigen receptor-expressing cells
|
|
US11191784B2
(en)
|
2020-03-11 |
2021-12-07 |
The Trustees Of The University Of Pennsylvania |
Methods and composition for gene delivery using an engineered viral particle
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CA3175392A1
(en)
|
2020-04-17 |
2021-10-21 |
Michael A. Caligiuri |
Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
|
|
EP3916388A1
(en)
|
2020-05-27 |
2021-12-01 |
Miltenyi Biotec B.V. & Co. KG |
Reagents for detection of chimeric antigen receptor cells
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
CA3184752A1
(en)
*
|
2020-06-12 |
2021-12-16 |
Nkarta, Inc. |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
KR20230040337A
(ko)
|
2020-06-19 |
2023-03-22 |
페이트 세러퓨틱스, 인코포레이티드 |
면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
|
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
|
MX2023002041A
(es)
*
|
2020-08-20 |
2023-04-27 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para mesotelina.
|
|
EP3964585A1
(en)
|
2020-09-03 |
2022-03-09 |
Miltenyi Biotec B.V. & Co. KG |
Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
|
|
WO2022049217A1
(en)
|
2020-09-04 |
2022-03-10 |
Miltenyi Biotec B.V. & Co. KG |
System for inducible expression of an adapter in immune cells
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体（car）的细胞的组合疗法
|
|
JP2023553815A
(ja)
|
2020-11-24 |
2023-12-26 |
ライエル・イミュノファーマ・インコーポレイテッド |
幼若化したｔ細胞を作製する方法、それを含む組成物、及びその使用方法
|
|
KR20230122618A
(ko)
|
2020-12-21 |
2023-08-22 |
알로젠 테라퓨틱스 인코포레이티드 |
프로테아제 활성화 cd45-게이트 car
|
|
EP4284822A1
(en)
*
|
2021-01-29 |
2023-12-06 |
Outpace Bio, Inc. |
Small molecule-regulated cell signaling expression system
|
|
US20240115608A1
(en)
*
|
2021-02-10 |
2024-04-11 |
The Regents Of The University Of California |
Immune receptors with synthetic co-stimulatory domains
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
GB202104030D0
(en)
*
|
2021-03-23 |
2021-05-05 |
Autolus Ltd |
Signalling system
|
|
US20240180969A1
(en)
*
|
2021-04-01 |
2024-06-06 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting hla-a*11 and methods of use thereof
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
GB202108366D0
(en)
|
2021-06-11 |
2021-07-28 |
Quell Therapeutics Ltd |
Multichain chimeric antigen receptor
|
|
US20230060292A1
(en)
|
2021-07-26 |
2023-03-02 |
Kite Pharma, Inc. |
Split chimeric antigen receptors and methods of use
|
|
WO2023044304A1
(en)
*
|
2021-09-15 |
2023-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
PE20241173A1
(es)
|
2021-10-14 |
2024-05-28 |
Arsenal Biosciences Inc |
Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
|
|
EP4416270A1
(en)
|
2021-10-15 |
2024-08-21 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023130462A1
(zh)
*
|
2022-01-10 |
2023-07-13 |
卡瑞济(北京)生命科技有限公司 |
靶向IL13Rα2的嵌合抗原受体及其用途
|
|
CN114736306B
(zh)
*
|
2022-03-01 |
2024-04-19 |
中国科学院深圳先进技术研究院 |
一种受化学调控的蛋白酶工具及其配套底物
|
|
EP4504243A1
(en)
|
2022-04-01 |
2025-02-12 |
Miltenyi Biotec B.V. & Co. KG |
A system for drug-inducible expression of a polynucleotide
|
|
EP4504799A1
(en)
|
2022-04-08 |
2025-02-12 |
Fate Therapeutics, Inc. |
Chimeric antigen receptor for tumor targeting
|
|
US20250228943A1
(en)
|
2022-04-08 |
2025-07-17 |
Fate Therapeutics, Inc. |
Cells having solid tumor targeting backbone and use thereof
|
|
EP4522751A1
(en)
|
2022-05-10 |
2025-03-19 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
US20250313815A1
(en)
*
|
2022-05-13 |
2025-10-09 |
Northwestern University |
Active loading of cargo entity into lipid bilayer particles using dimerization domains
|
|
WO2023222617A1
(en)
|
2022-05-16 |
2023-11-23 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
WO2024050325A2
(en)
*
|
2022-09-01 |
2024-03-07 |
Sri International |
Genetically engineered cd4 t-cells for in situ synthesis of proteins
|
|
IL319225A
(en)
|
2022-09-15 |
2025-04-01 |
Novartis Ag |
Treatment of autoimmune disorders using antigen receptor chemotherapeutics
|
|
EP4342488A1
(en)
|
2022-09-26 |
2024-03-27 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
KR102834479B1
(ko)
*
|
2022-11-04 |
2025-07-16 |
한국과학기술연구원 |
형광공명에너지전이 기반 car 활성 센싱용 바이오센서 및 그의 용도
|
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024158800A2
(en)
*
|
2023-01-24 |
2024-08-02 |
Ginkgo Bioworks, Inc. |
Immune cell stimulatory sequences
|
|
WO2024182539A1
(en)
|
2023-02-28 |
2024-09-06 |
Lyell Immunopharma, Inc. |
Methods of culturing reprogrammed cells
|
|
EP4626447A1
(en)
|
2023-03-31 |
2025-10-08 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
WO2024223847A1
(en)
|
2023-04-27 |
2024-10-31 |
Miltenyi Biotec B.V. & Co. KG |
Pseudotyped retroviral vector particle with anti-cd3 display
|
|
AU2024261890A1
(en)
|
2023-04-27 |
2025-10-09 |
Miltenyi Biotec B.V. & Co. KG |
Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
|
|
EP4470555A1
(en)
|
2023-05-31 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
WO2025008108A1
(en)
|
2023-07-06 |
2025-01-09 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025078492A1
(en)
|
2023-10-13 |
2025-04-17 |
Miltenyi Biotec B.V. & Co. KG |
Cd3-targeted nipah-pseudotyped lentiviral vector particles
|
|
EP4545963A1
(en)
|
2023-10-26 |
2025-04-30 |
Miltenyi Biotec B.V. & Co. KG |
Method for selecting antigen recognizing moieties having specificity for a target structure
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025224123A1
(en)
|
2024-04-25 |
2025-10-30 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptors specific for fibroblast activation protein
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|